ACHV - Achieve Life Sciences, Inc.
| Previous Close | 3.33 |
| Open | 3.30 |
| Bid | 3.25 x 900 |
| Ask | 3.49 x 1200 |
| Day's Range | 3.25 - 3.38 |
| 52 Week Range | 3.25 - 52.80 |
| Volume | 105,592 |
| Avg. Volume | 954,368 |
| Market Cap | 9.26M |
| Beta | 2.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.97 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.90 |
- ACCESSWIRE•8 days ago
Today's Research Reports on Stocks to Watch: Achieve Life Sciences and Pfizer
NEW YORK, NY / ACCESSWIRE / July 12, 2018 / Shares of Achieve Life Sciences exploded on Wednesday after the company announced the advancement of the Cytisine Development Program after its meeting with ...
- Benzinga•9 days ago
Achieve Life Sciences Shares Surge On Development Plan For Smoking Cessation Candidate
Achieve Life Sciences Inc (NASDAQ: ACHV) shares are skyrocketing as the clinical-stage biotech moves one step closer to filing a New Drug Application for its smoking cessation pipeline candidate cytisine. The company said it will conduct a Phase 2b optimization trial in about 250 smokers in the U.S., with various dosing schedules to determine efficacy, safety and compliance profiles.
- PR Newswire•9 days ago
Achieve Life Sciences Announces Advancement of Cytisine Development Program Following Meeting with the FDA
SEATTLE and VANCOUVER, British Columbia, July 11, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an update on the cytisine development program following a meeting conducted with the United States (U.S.) Food and Drug Administration (FDA). The meeting with the FDA on the non-clinical and clinical development plans has further defined Achieve's Phase 3 clinical program and expected future New Drug Application (NDA) submission. Based on the FDA's recommendations to further characterize cytisine dosing prior to NDA submission, Achieve plans to conduct a Phase 2b optimization trial in approximately 250 smokers in the U.S., with various cytisine dosing schedules to evaluate overall treatment efficacy, safety, and compliance profiles for cytisine.
- ACCESSWIRE•23 days ago
Today’s Research Reports on Stocks to Watch: Puma Biotechnology and Achieve Life Sciences
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Biotech stocks Puma Biotechnology and Achieve Life Sciences soared in Tuesday's trading session after each company had positive developments. Puma rose after ...
- Benzinga•23 days ago
Achieve Life Sciences Shares Rip Higher On Positive Data For Smoking Cessation Drug
Achieve Life Sciences Inc (NASDAQ: ACHV ) shares were posting double-digit gains Tuesday on roughly 83 times the stock's average volume. The stock was up 31 percent at the time of publication at $4.97. ...
- PR Newswire•24 days ago
Achieve Announces Positive Cytisine Data Demonstrating No Clinically Significant Drug-Drug Interaction
The study demonstrated that cytisine has no clinically significant interaction with any of the hepatic enzymes commonly responsible for drug metabolism nor clinically significant interaction with drug transporters. This suggests that cytisine may be administered with other medications without the need to modify the dose of the co-administered drug. Dr. Anthony Clarke, Chief Scientific Officer of Achieve commented: "We are very pleased with the results of these detailed studies.
- PR Newswire•last month
Achieve Life Sciences, Inc. Announces Closing of a $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
SEATTLE and VANCOUVER, British Columbia, June 19, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering was comprised of Class A Units, priced at a public offering price of $4.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $4.00 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of Series A preferred stock, which is convertible into 250 shares of common stock, and a five-year warrant to purchase 250 shares of common stock, also with an exercise price of $4.00 per share.
- PR Newswire•last month
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
SEATTLE and VANCOUVER, British Columbia, June 15, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering is comprised of Class A units, priced at a public offering price of $4.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $4.00 per share, and Class B units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of Series A preferred stock, which is convertible into 250 shares of common stock, and a five-year warrant to purchase 250 shares of common stock, also with an exercise price of $4.00 per share.
- PR Newswire•last month
Achieve Announces Publication of Cytisine Data for Next-Generation Cytisine Molecules
The University of Bristol strategic collaboration uses a combination of computational docking and chemical synthesis to design and generate precision chemical keys for important biological locks. Nicotinic acetylcholine receptors (nAChR) associated with acetylcholine-mediated neurotransmission have been linked to several neurological conditions and public health issues, notably tobacco addiction.
- Simply Wall St.•2 months ago
Should You Be Concerned About Achieve Life Sciences Inc’s (NASDAQ:ACHV) Shareholders?
In this article, I will take a quick look at Achieve Life Sciences Inc’s (NASDAQ:ACHV) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure ofRead More...
- PR Newswire•2 months ago
Achieve Life Sciences, Inc. Announces Reverse Stock Split
SEATTLE and VANCOUVER, British Columbia, May 23, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective on May 23, 2018, and shares will begin trading on the split-adjusted basis on the Nasdaq Capital Market under the Company's existing trading symbol "ACHV" at market open on May 24, 2018. The new CUSIP number following the reverse stock split will be 004468203.
- PR Newswire•2 months ago
Achieve Reports Financial Results for First Quarter 2018
SEATTLE and VANCOUVER, British Columbia , May 9, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- PR Newswire•2 months ago
Achieve Announces Patent Granted on Novel Formulation of Cytisine
SEATTLE and VANCOUVER, British Columbia, May 7, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that the UK Intellectual Property Office has granted Achieve a patent (no. 2550241) on cytisine succinate salt. Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisine.
- PR Newswire•4 months ago
Achieve Life Sciences Announces Cytisine Symposium at the 17th World Conference on Tobacco or Health
BOTHELL, Wash. and VANCOUVER, British Columbia, March 6, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), today announced that the World Conference on Tobacco or Health (WCTOH) will be holding a symposium on cytisine research at this year's annual conference, March 7-9th in Cape Town, South Africa. The cytisine symposium titled "Is a Globally Affordable Medication to Treat Tobacco Dependence Achievable? The Case of Cytisine." will be held on Friday, March 9th at 7:45am.
CNW Group•5 months agoAchieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
- PR Newswire•5 months ago
Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
BOTHELL, Wash. and VANCOUVER, British Columbia , March 1, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and ...
- CNW Group•5 months ago
Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
- PR Newswire•5 months ago
Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
The study, initiated in October 2017, evaluated the repeat-dose PK and PD effects of 1.5mg and 3mg cytisine in 24 healthy volunteer smokers aged 18-65 years when administered over the standard 25-day course of treatment. The PK results indicated expected increases in plasma concentration between the standard and higher doses of cytisine with no evidence of drug accumulation. Cytisine was well-tolerated and reported adverse events were mostly mild and short-lived.
CNW Group•5 months agoInnovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth Plans
Innovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth Plans
- Benzinga•5 months ago
A Day Trader's View On Why Bigger Is (Usually) Better
You may remember that I’ve been using 2018 as a year to experiment with t rading through an IRA account . It’s been a challenge so far, with only a starting balance of just over $8,000. But I was ready ...
- ACCESSWIRE•6 months ago
Achieve Life Sciences Making Progress in the Smoking Cessation Market, Recent Events
NEW YORK, NY / ACCESSWIRE / January 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
- PR Newswire•6 months ago
Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
BOTHELL, Washington and VANCOUVER, British Columbia, Jan. 24, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an amendment to their Technology Licence Agreement with the University of Bristol, United Kingdom. Achieve entered into a strategic collaboration in June 2017 with the University of Bristol to license certain patent and technology rights to explore next-generation cytisine-based therapies specifically related to smoking cessation. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years.
- CNW Group•6 months ago
Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories...
- Simply Wall St.•6 months ago
What Does Achieve Life Sciences Inc’s (NASDAQ:ACHV) Ownership Structure Look Like?
I am going to take a deep dive into Achieve Life Sciences Inc’s (NASDAQ:ACHV) most recent ownership structure, not a frequent subject of discussion among individual investors. When it comesRead More...
- Simply Wall St.•7 months ago
A Look At Achieve Life Sciences Inc (NASDAQ:ACHV) And The Healthcare Sector
Achieve Life Sciences Inc (NASDAQ:ACHV), a USD$16.05M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population andRead More...
